Table 1. Demographic and baseline characteristics of the participants.
| Characteristics | All | Sitagliptin dose‐up | Glimepiride dose‐up | P‐value* |
|---|---|---|---|---|
| n (Male/female) | 50 (31/19) | 25 (16/9) | 25 (15/10) | – |
| Age (years) | 63.1 ± 12.4 | 63.9 ± 10.3 | 62.4 ± 14.3 | 0.99 |
| BMI (kg/m2) | 25.1 ± 3.9 | 24.9 ± 4.1 | 25.3 ± 3.6 | 0.93 |
| SBP (mmHg) | 134 ± 15 | 132 ± 14 | 136 ± 16 | 0.45 |
| DBP (mmHg) | 78 ± 11 | 76 ± 13 | 80 ± 9 | 0.25 |
| BUN (mg/dL) | 15.6 ± 4.8 | 14.8 ± 4.6 | 16.4 ± 5.0 | 0.19 |
| Creatinine (mg/dL) | 0.77 ± 0.19 | 0.74 ± 0.18 | 0.81 ± 0.21 | 0.19 |
| HbA1c (%) | 7.4 ± 0.6 | 7.3 ± 0.5 | 7.5 ± 0.6 | 0.22 |
| TC (mg/dL) | 182 ± 27 | 185 ± 29 | 178 ± 23 | 0.21 |
| LDL‐C (mg/dL) | 102 ± 23 | 104 ± 27 | 99 ± 18 | 0.36 |
| HDL‐C (mg/dL) | 51 ± 13 | 55 ± 15 | 47 ± 10 | 0.05 |
| TG (mg/dL) | 143 ± 32 | 133 ± 71 | 157 ± 68 | 0.16 |
| Non‐HDL‐C (mg/dL) | 131 ± 28 | 131 ± 34 | 131 ± 22 | 0.92 |
| FPG (mg/dL) | 143 ± 32 | 142 ± 32 | 145 ± 33 | 0.68 |
| F‐IRI (μU/mL) | 8.1 ± 4.7 | 8.0 ± 4.6 | 8.3 ± 5.0 | 0.99 |
| HMW adiponectin (μg/mL) | 7.3 ± 3.5 | 7.0 ± 3.6 | 7.6 ± 3.5 | 0.54 |
| AA (μg/mL) | 196.9 ± 41.7 | 190.2 ± 31.6 | 203.3 ± 49.4 | 0.47 |
| EPA (μg/mL) | 82.6 ± 42.7 | 85.0 ± 33.5 | 80.3 ± 50.7 | 0.20 |
| DHA (μg/mL) | 154.3 ± 47.5 | 153.6 ± 42.5 | 155.0 ± 52.8 | 0.77 |
| EPA/AA ratio | 0.45 ± 0.27 | 0.46 ± 0.19 | 0.43 ± 0.33 | 0.16 |
| Dosage of glimepiride (mg/day) | 1.2 ± 0.5 | 1.2 ± 0.6 | 1.2 ± 0.5 | 0.99 |
| Metformin (n) | 25 | 14 | 11 | 0.40 |
| Dosage of metformin (mg/day) | 350 ± 388 | 400 ± 382 | 300 ± 395 | 0.24 |
AA, arachidonic acid; BMI, body mass index; DBP, diastolic blood pressure; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; F‐IRI, fasting immunoreactive insulin; FPG, fasting plasma glucose; HDL‐C, high‐density lipoprotein cholesterol; HMW adiponectin, high molecular weight adiponectin; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride. Mean ± standard deviation values are shown. *P‐values for differences between the sitagliptin and glimepiride groups.